
	Where results make sense

Topic: UCB (company)

Related Topics

American Broadcasting Company

The Walt Disney Company

Ford Motor Company

Livery Companies

British East India Company

Bad Company

list of companies

Fox Broadcasting Company

Companies in Atlas Shrugged

National Broadcasting Company

Dutch East India Company

East India Company

In the News (Thu 31 Dec 09)

Northern Trust

Marvin Harrison

Peter Chernin

Gary Locke

Match Play

Penelope Cruz

Mickey Rourke

AR Rahman

Danny Boyle

Hugh Jackman

	UCB SA - Company Profile - Insurance Business Review (Site not responding. Last check: 2007-10-05)
		UCB Films, meanwhile, is a global business dedicated to developing speciality and high performance film for selected markets including the food and beverage, labels, security products, industrial membrane, health and pharmaceutical industries.
		UCB Pharma confirmed in 2003 its role as a world player of the first rank in the therapeutic fields of "neurology/central nervous system" and "allergy/respiratory".
		UCB contributes to an improvement in the quality of life of large numbers of people, something of which we are particularly proud.
	www.insurance-business-review.com /companyprofile.asp?guid=EB58DCAF-08F2-4819-AA32-999DA1E029D3 (1208 words)

	Cytec to Buy UCB Chemicals Business for 1.5 Bln Euros (Site not responding. Last check: 2007-10-05)
		UCB shares rose 43 cents, or 1 percent, to 43.30 euros as of 11:52 a.m.
		The company produces building-block chemicals from which it makes composites and adhesives for the aerospace industry, coatings for metal, plastic, and wood, as well as polymer additives, and specialty chemicals used in treating water and in industrial processes.
		UCB expects the sale to be completed by the end of December, it said in an e-mailed statement.
	www.globalcomposites.com /news/news_fiche.asp?id=1441& (528 words)

	UCB Group
		UCB is a global biopharmaceutical leader with headquarters in Brussels, Belgium, specialising in the fields of central nervous system disorders, allergy and respiratory disease, immune and inflammatory disorders and oncology.
		June 29, 2005: Positive opinion for UCB's Xyrem® for the treatment of cataplexy in adults with narcolepsy
		June 24, 2005: FDA Approves UCB’s Keppra® for Use in Childhood Epilepsy
	www.ucb-group.com (262 words)

	UCB makes friendly offer for Celltech
		UCB had already entered into a licensing deal for the compound, called CDP 870, but the merger with Celltech would allow it to reap the most benefit should it reach the market and remove its reliance on partners.
		UCB has been hit by competition to its blockbuster antihistamine drug Zyrtec (cetirizine) after patent expiries in Europe, although it has high hopes for Keppra (levetiracetam) a drug for epilepsy which made 314 million last year and is tipped to put in 40 to 50 per cent growth in 2004.
		UCB said it will finance the acquisition through bank loans and said it is expected that the transaction will be earnings after the second year.
	www.drugresearcher.com /news/printNewsBis.asp?id=52194 (421 words)

	Boston.com / News / World / Europe / Cytec Buys UCB Chemicals Business (Site not responding. Last check: 2007-10-05)
		UCB said the U.S. company would probably have to sell around 10 percent of the businesses it was buying in order to satisfy competition regulators.
		UCB's shares were up 0.5 percent at 43.08 euros, after rising to 45.00 euros, their highest level since March 2002, as analysts welcomed the move.
		UCB's 3 billion euros in annual sales are evenly divided between pharmaceuticals and the films and chemicals business, although it derives most of its profits from pharmaceuticals.
	www.boston.com /news/world/europe/articles/2004/10/01/cytec_buys_ucb_chemicals_business?mode=PF (682 words)

	Cardiome reports first quarter results (Site not responding. Last check: 2007-10-05)
		The increase was mainly due to the recognition of the remaining balance of unamortized deferred revenue of $0.9 million ($0.1 million for Q1-2003) related to the upfront payment from UCB Farchim S.A ("UCB") and the amortization of deferred revenue of $1.0 million ($Nil for Q1-2003) related to the upfront payment from Fujisawa Healthcare, Inc. ("Fujisawa").
		UCB is evaluating whether it will advance any compound from our previous anti-tussive program to clinical trials.
		The Company's operational activities during Q1-2004 were financed mainly by its working capital carried forward from the preceding fiscal year and research collaborative fees collected from its partners, Fujisawa and UCB.
	www.forrelease.com /D20040517/to138.P1.05172004162416.25699.html (2514 words)

	UCB Announces Positive Results in Neurology and Inflammation Products (Site not responding. Last check: 2007-10-05)
		UCB (http://www.ucb-group.com) is a global pharmaceutical and specialty chemical leader with headquarters in Brussels, Belgium.
		UCB Pharma is a global biopharmaceutical leader, specialising in the fields of central nervous system disorders, allergy and respiratory diseases, immune and inflammatory disorders and oncology.
		UCB is listed on Euronext Brussels, and achieved sales of 3 billion and a net profit of 340 million in 2003.
	www.medicalnewstoday.com /medicalnews.php?newsid=17278&nfid=rssfeeds (446 words)

	UCB Research Inc.
		UCB Research, Inc., located in Cambridge, Massachusetts, is a cutting edge research and discovery company which supports UCB Pharma's drug development pipeline with therapeutic candidates for allergic and central nervous system disorders.
		UCB Research is a subsidiary of UCB Pharma, a global research-based pharmaceutical company with 6,500 employees based in Brussels, Belgium and with U.S. headquarters in Atlanta, Georgia.
		UCB Pharma is part of the UCB Group, which in addition to pharmaceuticals, includes a films and coatings sector, Surface Specialties.
	www.biospace.com /company_profile.cfm?CompanyID=219804 (231 words)

	UCB S.A.: No-Action Letter dated May 19, 2004
		UCB S.A. UCB is a pharmaceutical and specialty chemical company that does business through its approximately 50 subsidiaries in Europe, the Americas and Asia.
		UCB does not have any securities listed on any national securities exchange or quoted on The Nasdaq Stock Market, Inc. and UCB is not, and is not required to be, a reporting company under the Exchange Act.
		UCB's primary objective in structuring the Offer is to allow for participation by holders of the Ordinary Shares in the United Kingdom and the United States and holders of ADSs, while complying with the generally applicable requirements in those jurisdictions to the greatest extent practicable.
	www.sec.gov /divisions/marketreg/mr-noaction/ucb051904.htm (3753 words)

	European Firms Form Biotech Heavyweight (phillyBurbs.com) (Site not responding. Last check: 2007-10-05)
		UCB has a network of specialist physicians in the United States and Asia who already have relationships with UCB drug representatives.
		UCB shares closed 4.0 percent lower at 33.7 euros ($40.27) a share in Brussels, while Celltech closed 25.9 percent higher in London at 5.42 pounds ($9.59).
		Ando and Doliveux said they were confident that the enlarged company would be able to compete in the United States, in part because UCB already generates more than 40 percent of its sales there.
	www.phillyburbs.com /pb-dyn/news/24-05182004-302194.html (466 words)

	Celltech Group - Home
		UCB's vision is to build a global biopharmaceutical leader, based on a unique blend of innovation, entrepreneurship and proven experience, bringing to specialists first, new medicines to treat patients suffering from severe diseases.
		UCB focuses on innovative solutions for human healthcare brought to specialists in therapeutic areas where it aims to be among the world leaders.
		UCB is listed on Euronext Brussels, achieved sales of € 3,068 million and a net profit of € 362 million in 2004, including former Surface Specialties division.
	www.celltechgroup.com (145 words)

	MSN Money - CYT Key Developments: Investing
		UCB now owns approximately 12.5% of the outstanding shares of the Company's, and has entered into a stockholders agreement, which provides for UCB to reduce its stake within 5 years.
		UCB and Cytec have also agreed to enter into a stockholders agreement which will provide for UCB to reduce its stake within 5 years and contain other customary terms and provisions.
		The Company's full year normalized EPS objective is expected to be in a range of $2.05 to $2.15, with the third quarter expected to be in a range of $0.52 to $0.57.
	news.moneycentral.msn.com /ticker/sigdev.asp?Symbol=CYT (4272 words)

	bbt online for the best business
		UCB has been diversifying in Eastern Europe for quite some years now, and now that these countries have joined the European Union, the relationship is getting even more tight.
		The UCB Group, one of the largest enterprises in Belgium, is a world-class pharmaceutical and specialty chemical company.
		One of these companies were the owner of the oldest chemical factory in Belgium, built in the 18th century on a site at Drogenbos near Brussels, and which is still in operation.
	www.bbt.be /Library/extranews/extranews082004.cfm (3501 words)

	Democrat and Chronicle (Site not responding. Last check: 2007-10-05)
		The acquisition is part of a plan to strengthen UCB as a global pharmaceutical company, Bungay said in an e-mail.
		The companies also announced Tuesday that Celltech had granted to USB worldwide rights for the development and marketing of CDP870, Celltech’s promising drug candidate for the treatment of Crohn’s disease and rheumatoid arthritis.
		UCB is a pharmaceutical and specialty chemical company that is based in Brussels, Belgium.
	www.democratandchronicle.com /biznews/forprint/05192K4A5FF_business.shtml (364 words)

	UCB hikes R&D budget for 2005
		The company’s board approved a 2005 R&D budget for the group of 480 million ahead of the New Year, an increase of 58.9 per cent on 2004's 302 million.
		UCB has transformed itself over the last few years, progressing inexorably towards becoming a pharmaceutical pure-play by shedding various chemicals units.
		The company embarked on the path towards metamorphosis back in 2002 with its acquisition of speciality chemicals business Solutia for $500 million, splitting the group's sales evenly between chemicals and pharmaceuticals, and setting it up to make a big pharma acquisition.
	www.drugresearcher.com /news/printNewsBis.asp?id=57022 (343 words)

	UCB-Bioproducts (Site not responding. Last check: 2007-10-05)
		Currently, UCB-Bioproducts is providing The Medicines Company with bivalirudin for Angiomax for use in two phase III trials for patients with myocardial infarction and angioplasty patients experiencing heparin induced thrombocytopenia.
		The Medicines Company was founded in 1996 by a team of experienced pharmaceutical executives to acquire, develop and commercialize selected pharmaceutical products in late stages of development.
		The Company is also focused on specialty anti-infectives and is developing a second product, CTV-05, a proprietary biotherapeutic agent with a potentially broad range of applications in the treatment of gynecological and reproductive infections.
	www.ucb-bioproducts.com /angiomax_pr.htm (585 words)

	Millennium Pharmaceuticals, Inc. :: Millennium and UCB Pharma Enter Into Agreement to Collaborate on Two Biotherapeutic ...
		The Company's research, development and commercialization activities are focused in three therapeutic areas: oncology, cardiovascular, and inflammation.
		UCB Pharma is part of the UCB Group of companies, a global pharmaceutical and specialty chemical company with headquarters in Brussels, Belgium.
		UCB Pharma is a leading biopharmaceutical company, specialising in the fields of central nervous system disorders, allergy and respiratory disease, immune and inflammatory disorders and oncology.
	sev.prnewswire.com /biotechnology/20050125/NYTU05925012005-1.html (671 words)

	Company News On Call (Site not responding. Last check: 2007-10-05)
		The merger between the Winston-Salem, N.C.-based Southern National and the Whiteville, N.C.-based UCB will form a financial institution with more than $25 billion in assets, the largest share of deposits in North Carolina, at approximately 20%, and the third largest share of deposits in South Carolina, at 11%.
		UCB's banking subsidiaries, United Carolina Bank and United Carolina Bank of South Carolina, will merge into Branch Banking and Trust Company (BB&T) and Branch Banking and Trust Company of South Carolina, respectively, the principal banking subsidiaries of Southern National.
		Under the terms of the agreement, UCB has granted to Southern National an option to purchase a number of UCB shares up to 19.9% of currently outstanding shares.
	www.prnewswire.com /cgi-bin/stories.pl?ACCT=105&STORY=/www/story/41397 (598 words)

	INPHARMATICA ANNOUNCES BIOPENDIUM ONLINE SUBSCRIPTION AGREEMENT WITH UCB PHARMA - Inpharmatica (Site not responding. Last check: 2007-10-05)
		UCB Pharma Inc. is itself a division of UCB Pharma, one of Europe’s leading speciality pharmaceutical companies.
		Inpharmatica Ltd is a selective drug discovery company that is applying its expertise in structural and computational biology, and medicinal chemistry to the identification of quality drug targets, chemical leads and drug candidates, thereby reducing attrition in the drug discovery process.
		The Company’s lead discovery program is focused upon the development of 16 novel Nuclear Receptors (“NR’s”), a family of proteins widely considered to be both druggable and of high therapeutic interest.
	www.inpharmatica.co.uk /news/2003/301003.htm (652 words)

	Ucb Pharmaceutical Company Intelligence Report - Market Research Report
		Two-thirds of the UCB Group expenditure on research and development are in the Pharma Sector where UCB is engaged in R&D in the fields of allergic/respiratory diseases and disorders of the central nervous system.
		UCB's present structure comprises the parent company and about 130 subsidiaries and affiliates worldwide, mainly in Western Europe but also in the Americas and Asia.
		Pharmaceutical Company Intelligence Reports provide a full review of the company's activities, from its origins to its latest corporate activity, including mergers and acquisitions, agreements, divestitures, major purchasing contracts and litigation.
	www.mindbranch.com /products/P16-483.html (296 words)

	Bloomberg.com: Europe
		Adding the UCB business, with 2003 sales of about 1.1 billion euros, or $1.4 billion, would boost Cytec to about the 16th-largest chemical company by revenue in the U.S. The UCB chemicals business includes resins such as those curable by ultraviolet light, used to coat fiber-optic cable for telecommunication networks.
		UCB has risen 23 percent since the company bought Celltech in May and said it would sell some units.
		UCB previously traded at a discount because it combined chemicals and drugs under one roof and will need positive news about its drug pipeline to maintain the gain in share value, Van den Bossche said at Petercam.
	quote.bloomberg.com /apps/news?pid=10000085&sid=a2se3pWePaXI&refer=europe (774 words)

	Versata > Company > Press Releases
		UCB believes Versata allowed them to deploy its customer relationship management system more quickly than other methods.
		Chia goes on to state, "By helping to facilitate teamwork between the business area of UCB and our Information Systems department, Versata was the key to rapidly deploying a project of this magnitude," he said.
		United California Bank is a UFJ Group company, one of the largest financial institutions in the world.
	www.versata.com /company/press_release.cfm?filename=080701.htm (871 words)

	[No title] (Site not responding. Last check: 2007-10-05)
		The company's size and its apparent maturity were clearly attractions for UCB, a mid-sized pharmaceutical manufacturer in Brussels best known for its blockbuster antihistamine drug Zyrtec.
		The company has an extremely promising compound, CDP870, that is well into clinical trials both for Crohn's disease (due to launch in 2006) and for rheumatoid arthritis (scheduled for launch in 2007).
		According to Celltech, UCB was able to come up with terms that are equivalent to those of the Pfizer deal in terms of net present value.
	www.nature.com /news/2004/040621/pf/nbt0704-787_pf.html (798 words)

	UCB-Bioproducts (Site not responding. Last check: 2007-10-05)
		The company currently offers one of the largest capacities available globally for the development and manufacturing of synthetic peptides as APIs.
		For more than 30 years, the company has provided the industry's widest range of capabilities related to the manufacturing of synthetic peptide-based active pharmaceutical ingredients.
		UCB-Bioproducts is a division of UCB S.A., a publicly traded company on the Euronext stock exchange, headquartered in Brussels.
	www.ucb-bioproducts.com /press_releases/pr_new_facility_2_03.htm (520 words)

	NetSci: The Biotech YellowPages - UCB Research, Inc. (Site not responding. Last check: 2007-10-05)
		UCB Corporation was established in1928 as Union Chimique Belge
		UCB is a world scale pharmaceutical and chemical group which is active in three industrial sectors: the Pharma sector, the Chemical sector and the Film sector.
		UCB's research-based activities in these sectors aim to be at the service of man, seeking to promote his well-being and quality of life.
	www.netsci.org /Resources/Biotech/Yellowpages/U/ucb.html (66 words)

	Company News - September 2000 (Site not responding. Last check: 2007-10-05)
		UCB Chemicals USA, based in Smyrna, Ga., has announced that it is suspending the sales control previously placed on its four major acrylated multifunctional monomers, TMPTAN, TRPGDA, HDODA, and TMPEOTA, all of which are used in coatings for glass.
		In addition, UCB recently utilized several de-bottlenecking measures at its plant in Pampa, Texas, which increased the plant’s output to record levels.
		According to the company, the purpose of the essay contest was to provide a positive platform for students to get involved with their communities, as well as build stronger relationships within the cities in which TRACO is located.
	www.usglassmag.com /backissues/0009/0009companynews.html (589 words)

	Berkeley Business Guide #22-International Business Research - Business & Economics Library - UC Berkeley
		Company listing includes a company history, description of the business and property, financial statements, management, debt, capital and other key data.
		Company information includes descriptive narrative, a history of the company, key officers, subsidiaries, competitors, latest news stories about company.
		Record numbers prefixed with SRI are on microfiche and are filed in cabinets across from the Reference Desk in Long Library, while those that are prefixed with ISS and ASI are housed at GSSI in Doe.
	www.lib.berkeley.edu /BUSI/bbg22.html (1195 words)

	[No title]
		UCB will host occasional visits by Company personnel for the purpose of research interaction.
		UCB and Company shall observe the laws and regulations of the U.S. and Japan, including, but not limited to, both U.S. and Japanese export administration regulations.
		Agreed by: UCB Company _______________________ ________________________ Professor Shankar Sastry Chairman, Electrical Engineering and Computer Sciences University of California, Berkeley Berkeley, CA 94720-1774 (tel) 510-642-2967 (fax) 510-643-6694 _______________________ ________________________ Date Date BISC Strategic Program BISC Strategic Partners pay $250,000 per year for a committed three years membership.
	www-bisc.cs.berkeley.edu /BISCProgram/BISCboilerplate.beecsa.agree-2.doc (454 words)

Try your search on: Qwika (all wikis)